ECSP024365A - Moleculas mutantes solubles ctla4 y sus aplicaciones - Google Patents

Moleculas mutantes solubles ctla4 y sus aplicaciones

Info

Publication number
ECSP024365A
ECSP024365A EC2002004365A ECSP024365A ECSP024365A EC SP024365 A ECSP024365 A EC SP024365A EC 2002004365 A EC2002004365 A EC 2002004365A EC SP024365 A ECSP024365 A EC SP024365A EC SP024365 A ECSP024365 A EC SP024365A
Authority
EC
Ecuador
Prior art keywords
ctla4
mutant molecules
applications
amino acid
molecules
Prior art date
Application number
EC2002004365A
Other languages
English (en)
Inventor
Juergen Bajorath
Robert J Peach
Joseph R Naemura
Peter S Linsley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ECSP024365A publication Critical patent/ECSP024365A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención ofrece las moléculas mutantes CTLA4 solubles que se ligan con mayor intensidad a los antígenos CD80 y/o CD86 que a los CTLA4 de tipo agresivo o CTLA4 Ig no mutados. Las moléculas CTLA4 solubles tienen una primera secuencia de aminoácido conteniendo el dominio extracelular de CTLA4, donde ciertos residuos de aminoácidos son mutados en las regiones 825- R33 Y M97-G107. Las molécular mutantes de la invención pueden también incluir una segunda secuencia de aminoácidos que aumentan la solubilidad de las moléculas mutantes.
EC2002004365A 2000-05-26 2002-11-26 Moleculas mutantes solubles ctla4 y sus aplicaciones ECSP024365A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26

Publications (1)

Publication Number Publication Date
ECSP024365A true ECSP024365A (es) 2003-03-31

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2002004365A ECSP024365A (es) 2000-05-26 2002-11-26 Moleculas mutantes solubles ctla4 y sus aplicaciones

Country Status (41)

Country Link
EP (3) EP1248802B9 (es)
JP (1) JP4328525B2 (es)
KR (2) KR100889887B1 (es)
CN (2) CN101255192A (es)
AR (1) AR031699A1 (es)
AT (1) ATE271066T1 (es)
AU (2) AU6346601A (es)
BE (1) BE2011C041I2 (es)
BR (1) BRPI0111191B8 (es)
CA (1) CA2409748C (es)
CY (2) CY2011019I1 (es)
CZ (1) CZ304451B6 (es)
DE (2) DE60104282T2 (es)
DK (1) DK1248802T3 (es)
EC (1) ECSP024365A (es)
EE (2) EE05458B1 (es)
EG (1) EG24459A (es)
ES (2) ES2571852T3 (es)
FR (1) FR11C0053I2 (es)
GE (1) GEP20053658B (es)
HK (1) HK1048126B (es)
HU (2) HU228137B1 (es)
IL (1) IL152315A (es)
LT (1) LT5133B (es)
LU (1) LU91902I2 (es)
LV (1) LV12994B (es)
MX (1) MXPA02011534A (es)
MY (1) MY136113A (es)
NO (2) NO330797B1 (es)
PE (1) PE20011338A1 (es)
PL (1) PL206267B1 (es)
PT (1) PT1248802E (es)
RU (1) RU2283847C2 (es)
SI (1) SI1248802T1 (es)
SK (1) SK288131B6 (es)
TR (1) TR200402703T4 (es)
TW (2) TWI314933B (es)
UA (1) UA87432C2 (es)
UY (1) UY26723A1 (es)
WO (1) WO2001092337A2 (es)
ZA (1) ZA200208944B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
TWI322153B (en) 2000-07-03 2010-03-21 Bristol Myers Squibb Co Methods for treating rheumatic diseases using a soluble ctla4 molecule
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
DK1397153T3 (da) 2001-05-23 2008-05-26 Bristol Myers Squibb Co Fremgangsmåde til beskyttelse af allogent ö-celle-transplantat ved anvendelse af oplöselige CTLA4-mutantmolekyler
EP1496931A4 (en) * 2002-04-19 2009-07-01 Bristol Myers Squibb Co METHODS OF TREATING AUTOIMMUNE DISEASE USING SOLUBLE CTLA4 MOLECULE AND ARMM OR NSAID
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
AU2003303394B2 (en) * 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
CA2511520A1 (en) * 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
AU2003299971A1 (en) 2002-12-30 2004-07-29 Amgen Inc. Combination therapy with co-stimulatory factors
WO2005044188A2 (en) 2003-10-27 2005-05-19 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
ES2439641T3 (es) 2005-12-20 2014-01-24 Bristol-Myers Squibb Company Composiciones y procedimientos de producción de una composición
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
KR101546441B1 (ko) 2006-12-20 2015-08-24 엠엠알글로벌, 인코포레이티드 항체 및 이들의 제조 및 사용 방법
EP2612867A1 (en) * 2007-11-01 2013-07-10 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
CN107056951A (zh) * 2008-10-02 2017-08-18 阿帕特夫研究和发展有限公司 Cd86拮抗物多靶点结合蛋白
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US8642557B2 (en) 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
CA2827492A1 (en) 2011-02-23 2012-08-30 Amgen Inc. Cell culture media for uvc exposure and methods related thereto
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
US9758566B2 (en) 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
AU2013260172B2 (en) * 2012-05-11 2017-11-23 Medimmune Limited CTLA-4 variants
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
KR20150033703A (ko) * 2012-06-27 2015-04-01 오르반 바이오테크 엘엘씨 당뇨병 치료를 위한 ctla4 융합 단백질
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
EP3094735A1 (en) 2014-01-13 2016-11-23 Amgen Inc. Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
IL319240A (en) 2014-06-04 2025-04-01 Amgen Inc Methods for collecting mammalian cell cultures
HUE049201T2 (hu) 2014-12-01 2020-09-28 Amgen Inc Eljárás glikoprotein glikántartalmának befolyásolására
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
US11319359B2 (en) 2015-04-17 2022-05-03 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
EP3347486A4 (en) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
CN108350416A (zh) 2015-11-09 2018-07-31 百时美施贵宝公司 操纵在cho细胞中产生的多肽的品质属性的方法
EP4667012A2 (en) 2016-09-19 2025-12-24 OncoC4, Inc. Cd80 and cd86 binding protein compositions and uses thereof
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
MX2019012567A (es) 2017-04-20 2020-02-13 Egenesis Inc Metodos para generar animales geneticamente modificados.
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
CA3087149A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN115227824A (zh) * 2018-11-12 2022-10-25 中南大学湘雅二医院 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
CA3152665A1 (en) 2019-08-27 2021-03-04 Tonix Pharma Limited Modified tff2 polypeptides
TW202128745A (zh) 2019-12-06 2021-08-01 美商再生元醫藥公司 抗ｖｅｇｆ蛋白組合物及其製備方法
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
AU2021293591A1 (en) 2020-06-18 2023-01-19 Regeneron Pharmaceuticals, Inc. Heavy peptide approach to accurately measure unprocessed C-terminal lysine
CA3189533A1 (en) 2020-07-28 2022-02-03 Seagen Inc. Methods and systems for producing polypeptides
JP2025500887A (ja) 2021-12-16 2025-01-15 ブリストル－マイヤーズ スクイブ カンパニー ウイルス不活化用界面活性剤
KR20240167715A (ko) 2022-03-02 2024-11-27 리제너론 파아마슈티컬스, 인크. 고역가 항체의 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
DE122007000078I2 (de) 1991-06-27 2011-01-13 Bristol Myers Squibb Co CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
AU1102000A (en) * 1998-10-07 2000-04-26 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
TWI322153B (en) * 2000-07-03 2010-03-21 Bristol Myers Squibb Co Methods for treating rheumatic diseases using a soluble ctla4 molecule

Also Published As

Publication number Publication date
WO2001092337A2 (en) 2001-12-06
CN1309735C (zh) 2007-04-11
CZ20023892A3 (cs) 2003-09-17
EP1536234A2 (en) 2005-06-01
WO2001092337A3 (en) 2002-05-10
PL206267B1 (pl) 2010-07-30
SK288131B6 (sk) 2013-10-02
CA2409748C (en) 2008-09-16
ES2225549T3 (es) 2005-03-16
CY1117625T1 (el) 2017-04-26
LV12994B (en) 2003-08-20
EE05557B1 (et) 2012-08-15
EE05458B1 (et) 2011-08-15
CN101255192A (zh) 2008-09-03
BE2011C041I2 (es) 2020-08-20
DE122011100063I1 (de) 2012-06-14
PT1248802E (pt) 2004-11-30
DE60104282D1 (de) 2004-08-19
SK15702002A3 (sk) 2004-01-08
RU2283847C2 (ru) 2006-09-20
IL152315A (en) 2010-04-15
TWI314933B (en) 2009-09-21
KR100895134B1 (ko) 2009-05-04
HUS1300012I1 (hu) 2016-08-29
HU228137B1 (en) 2012-12-28
ATE271066T1 (de) 2004-07-15
MXPA02011534A (es) 2004-08-12
UA87432C2 (uk) 2009-07-27
HK1048126B (en) 2005-03-04
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
HK1071931A1 (en) 2005-08-05
BRPI0111191B8 (pt) 2021-05-25
FR11C0053I2 (fr) 2013-01-11
BRPI0111191B1 (pt) 2019-12-31
SI1248802T1 (en) 2005-02-28
CN1441810A (zh) 2003-09-10
NO2011027I1 (no) 2012-01-09
PE20011338A1 (es) 2002-01-13
EP1536234B1 (en) 2016-03-16
JP2004511213A (ja) 2004-04-15
EP1536234A3 (en) 2009-06-03
EP3029062A1 (en) 2016-06-08
CA2409748A1 (en) 2001-12-06
LT2002114A (en) 2003-12-29
KR100889887B1 (ko) 2009-03-24
ES2571852T3 (es) 2016-05-27
HUP0302201A3 (en) 2010-01-28
EP1248802B9 (en) 2005-05-11
HUP0302201A2 (hu) 2003-10-28
NO2011027I2 (es) 2011-12-15
LT5133B (lt) 2004-05-25
FR11C0053I1 (es) 2012-01-13
TR200402703T4 (tr) 2004-11-22
EP1248802B1 (en) 2004-07-14
AU2001263466C1 (en) 2006-10-26
IL152315A0 (en) 2003-05-29
BR0111191A (pt) 2004-07-06
KR20030009502A (ko) 2003-01-29
JP4328525B2 (ja) 2009-09-09
TWI319405B (en) 2010-01-11
PL366231A1 (en) 2005-01-24
CZ304451B6 (cs) 2014-05-14
TW200906857A (en) 2009-02-16
AU2001263466B2 (en) 2006-04-27
AU6346601A (en) 2001-12-11
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
MY136113A (en) 2008-08-29
GEP20053658B (en) 2005-11-10
DK1248802T3 (da) 2004-11-15
UY26723A1 (es) 2001-12-28
HK1048126A1 (en) 2003-03-21
EE200200659A (et) 2004-06-15
NO20025656L (no) 2002-11-25
NO330797B1 (no) 2011-07-18
AR031699A1 (es) 2003-10-01
NO20025656D0 (no) 2002-11-25
ZA200208944B (en) 2004-02-13
EG24459A (en) 2009-07-16
CY2011019I1 (el) 2016-12-14
DE60104282T2 (de) 2005-10-13
EE201100050A (et) 2011-10-17

Similar Documents

Publication Publication Date Title
ECSP024365A (es) Moleculas mutantes solubles ctla4 y sus aplicaciones
CY1106532T1 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
DE60131021D1 (de) Klebstoffzusammensetzungen mit selbstorganisierenden molekülen, klebstoffe, gegenstände und verfahren
CY1114626T1 (el) Μεθοδοι κυκλοπολυαιθυλενογλυκολιωσης και πρωτεϊνες/πεπτιδια που παραγονται με αυτες τις μεθοδους
CY1109649T1 (el) Αντιγονα και συνθεσεις απο neisseria
DE60236861D1 (de) Kombinatorische bibliotheken von monomerdomänen
ATE304583T1 (de) Klebstoffzusammensetzungen aus pflanzlichem protein
CY1110530T1 (el) Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων
CY1109068T1 (el) Υποκατεστημενες πυριδινυλαμινες
DK1171417T3 (da) Fremgangsmåde til fremstilling af 3-aryloxy-3-arylpropylaminer og mellemprodukter deraf
DK1255826T3 (da) Automatisering af proteindesign for proteinbiblioteker
CY1105194T1 (el) Φωσφονικα παραγωγα γλυκοπεπτιδιων
CY1107759T1 (el) Λυοφιλισμενη συνταγοποιηση που περιλαμβανει ολανζαπινη
ATE509949T1 (de) Metastasisch spezifische peptide und ihre diagnostischen und therapeutischen anwendungen
WO2003025119A3 (en) Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
NO20031860L (no) Kahalalid F
PA8508301A1 (es) Inhibidores de la proteina c del procolageno
MXPA05013268A (es) Composiciones de poliacetal y de polivinilbutiral y mezclas que tienen propiedades superficiales mejoradas y articulos elaborados a partir de estas.
DE60025494D1 (de) Epothilon zusammensetzungen
CY1110139T1 (el) Γλυκοπεπτιδικα αντιβιοτικα
FI20000219A7 (fi) Antistaattinen biohajoava muovikalvo ja menetelmä sen valmistamiseksi
ES1048892Y (es) Expositor de llaveros o articulos similares.